Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37.2% | 23.8% | 19.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32% | 37.4% | 27.2% | 46.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,259.3% | -531.7% | -2,124.5% | -1,649.4% |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 1,123.9% | -852.7% | 1,326.8% | -472.1% |
| EPS Diluted | 0.21 | -0.25 | 0.3 | -0.094 |
| % Growth | 184% | -183.3% | 418.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |